We are live on ! Find out more
LAB icon

Standard BioTools

65 hedge funds and large institutions have $42.5M invested in Standard BioTools in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.68% less ownership

Funds ownership: 56.8%49.12% (-7.7%)

24% less funds holding

Funds holding: 8665 (-21)

39% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 28

39% less capital invested

Capital invested by funds: $70.2M → $42.5M (-$27.7M)

54% less call options, than puts

Call options by funds: $44K | Put options by funds: $96K

84% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 25

Holders
65
Holders Change
-21
Holders Change %
-24.42%
% of All Funds
1.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
17
Reduced
28
Closed
25
Calls
$44K
Puts
$96K
Net Calls
-$52K
Net Calls Change
+$191K

LAB Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2022, worth a combined $42.5M — down 39% from $70.2M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of LAB and 4 opened new positions — a net loss of 21 holders — while 28 trimmed existing stakes and 17 added.

The largest buyer was Jennifer C. Price, adding an estimated $921K. The largest seller was RA Capital Management, exiting entirely with an estimated $3.18M sold.

  • 65 institutional investors held Standard BioTools (LAB) as of Q3 2022, down from 86 in Q2 2022.
  • Funds reported $42.5M of Standard BioTools stock for Q3 2022, down 39% quarter-over-quarter.
  • 4 funds opened new Standard BioTools positions in Q3 2022 and 25 closed out, a net change of -21 holders.
  • The largest Standard BioTools buyer in Q3 2022 was Jennifer C. Price, an estimated $921K added.
  • The largest Standard BioTools seller in Q3 2022 was RA Capital Management, an estimated $3.18M sold.

Based on aggregated 13F filings for Q3 2022.